Immuno-Oncology Drugs Market Forecast Highlights Expansion From $136.15 Billion To $226.3 Billion Through 2030
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Immuno-Oncology Drugs Market Value Expansion And Long-Term Growth Outlook
The market for immuno-oncology drugs has experienced rapid expansion over the past few years. Its value is projected to increase from $120.37 billion in 2025 to $136.15 billion in 2026, reflecting a compound annual growth rate (CAGR) of 13.1%. This historic growth has been driven by factors such as the constrained supply of these therapies, a dependence on traditional chemotherapy, a rising incidence of cancers including melanoma and lung cancer, an uptick in oncology-related research programs, and early-stage regulatory clearances for monoclonal antibodies.
The immuno-oncology drugs market is anticipated to experience significant expansion over the coming years, with projections indicating it will reach $226.31 billion by 2030, driven by a compound annual growth rate (CAGR) of 13.5%. This forecasted growth is fueled by advancements such as the creation of bispecific antibodies and oncolytic virus therapies, broader deployment of personalized immunotherapy options, greater investments in adoptive cell transfer methods, increased healthcare spending dedicated to cancer care, and the incorporation of digital tools for patient observation and clinical study management. Key trends shaping this period include the widespread use of immune checkpoint inhibitors across diverse cancer types, accelerated development of cancer vaccines and adoptive cell treatments, heightened emphasis on tailored immuno-oncology approaches, expansion of immunotherapy programs within hospitals and ambulatory surgical centers, and a surge in clinical trials and research activity focusing on monoclonal antibodies.
Download A Free Sample Report For Comprehensive Market Insights:
Immuno-Oncology Drugs Market Demand Drivers: What Is Fueling Industry Growth?
The anticipated rise in cancer diagnoses will likely accelerate the expansion of the immuno-oncology drugs market in the future. Cancer involves the uncontrolled growth of abnormal cells, which can invade other parts of the body and disrupt normal physiological processes. An increase in cancer cases is driven by factors like an aging demographic, lifestyle shifts, and enhanced screening techniques that detect the disease earlier. Immuno-oncology medications advance this trend by activating the immune system to precisely identify and destroy malignant cells, offering more accurate and effective therapeutic approaches. For example, in 2023, Cancer Australia, a government agency based in Australia, reported that there were approximately 164,694 new cancer diagnoses and 51,269 fatalities, with the most prevalent types being prostate, breast, melanoma, colorectal, and lung cancers, while rarer forms represented roughly one-third of all diagnoses and accounted for 42% of deaths. Consequently, the growing frequency of cancer occurrences is fueling the progress of the immuno-oncology drugs market.
Immuno-Oncology Drugs Market Segment Landscape: Which Areas Lead Market Development?
The immuno-oncology drugs market covered in this report is segmented –
1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Other Types
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors
3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies
4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
5) By Other Types: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies
Immuno-Oncology Drugs Market Innovation Trends: Which Developments Are Transforming The Industry?
Major pharmaceutical firms in the immuno-oncology sector are forming alliances aimed at jointly developing and bringing to market a new checkpoint antibody, with the goal of boosting the effectiveness of cancer therapies. Such strategic partnerships facilitate innovation by enabling the exchange of expertise across different disciplines, which accelerates the creation of combination therapies, customized treatment plans, and advanced drug delivery systems. As an example, in March 2023, BioNTech SE, headquartered in Germany, entered into an agreement with OncoC4 Inc, a US-based pharmaceutical organization, to jointly develop and commercialize the anti-CTLA-4 monoclonal antibody candidate ONC-392. This collaboration is intended to expand treatment possibilities for patients with various solid tumors.
Immuno-Oncology Drugs Market Industry Leaders And Market Competition
Major companies operating in the immuno-oncology drugs market are F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals.
Access The Complete Immuno-Oncology Drugs Market Report:
Immuno-Oncology Drugs Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the immuno-oncology drugs market in 2025. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
